Grifols S.A. declares $0.1404 dividend
Dividend Declaration: Grifols S.A. has declared a dividend of $0.1404 per share, with a forward yield of 5.25%.
Payment Details: The dividend is payable on August 20 for shareholders recorded by August 12, with the ex-dividend date also set for August 12.
Trade with 70% Backtested Accuracy
Analyst Views on GRFS
About GRFS
About the author
Grifols Obtains FDA Approval to Introduce Fesilty in the US by Mid-2026
FDA Approval: Grifols, S.A. has received FDA approval for Fesilty, a human fibrinogen product aimed at treating acute bleeding in patients with congenital fibrinogen deficiency.
Launch Timeline: The product is expected to be launched in the U.S. in the first half of 2026.
Company Statement: Dr. Jörg Schüttrumpf, CEO of Biotest AG, expressed pride in their contribution to enhancing access to life-saving fibrinogen therapies globally.
Stock Performance: Grifols' stock (GRFS) is currently trading at $8.99, reflecting a 0.84 percent increase on the Nasdaq.
Daily Upgrade Report for Validea's Joseph Piotroski Strategy - November 26, 2025
Validea's Upgrades: Today's upgrades for Validea's Book/Market Investor model highlight significant changes in ratings for stocks like Grifols SA, Invesco Ltd, and Molson Coors Beverage Co, reflecting improved fundamentals and valuations.
Grifols SA: The stock rating for Grifols SA increased from 0% to 90%, indicating strong interest based on its financial health and valuation in the biotechnology sector.
Invesco Ltd: Invesco Ltd's rating improved from 0% to 80%, suggesting a positive outlook based on its fundamentals in the investment services industry.
Molson Coors Beverage Co: Molson Coors Beverage Co saw its rating rise from 0% to 90%, demonstrating strong interest due to its financial performance in the alcoholic beverages market.
